Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints ...

Morning finger stiffness can be a subtle sign of early arthritis. Learn what to watch for and how early intervention can help ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

Medically reviewed by Anita C. Chandrasekaran, MD Psoriatic arthritis (PsA) is a chronic (long-lasting) condition that ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.